Veterinary care company Dechra announced on Nov. 17, 2026, that it has completed its acquisition of U.S.-based animal health biotechnology firm Gallant Pet Inc.
Deal details and confidential terms
Dechra completed the transaction to acquire Gallant Pet Inc, a developer of off-the-shelf mesenchymal stromal cell (MSC) therapies designed for pets.
The financial details of the transaction were not disclosed, with both parties agreeing to keep the terms confidential.
Regenerative therapy pipeline
Gallant develops ready-to-use MSC therapies aimed at working with natural biological processes to target chronic and complex conditions in animals.
According to the press release, the first innovation from Gallant's pipeline is expected as early as 2027.
Leadership statements
Dr. Cathy Knupp, Chief Scientific Officer at Dechra, described the deal as a strategic investment to expand veterinary treatment options by combining Dechra's global reach with Gallant's regenerative medicine platform.
Dr. Linda Black, CEO of Gallant, stated that joining Dechra aligns with Gallant's vision to make regenerative medicine accessible to pets in need.
Key facts and where they come from
- Dechra completed the acquisition of U.S.-based animal health biotechnology company Gallant Pet Inc.
Dechra, a global leader in veterinary specialty care, today completed its acquisition of Gallant Pet Inc (Gallant), a U.S.-based animal health biotechnology company
- Gallant develops off-the-shelf mesenchymal stromal cell (MSC) therapies for pets.
pioneering off-the-shelf mesenchymal stromal cell (MSC) therapies for pets.
- The financial terms of the acquisition remain confidential.
The transaction has been finalized and both parties have agreed that the terms of the transaction will remain confidential.
- The first innovation from Gallant's pipeline is anticipated in 2027.
The first innovation from the pipeline is anticipated as early as 2027.
The catch
- The announcement does not state the acquisition price or financial terms, as both companies agreed to keep them confidential.
- The first therapeutic product from Gallant's pipeline is not expected to launch until as early as 2027.
